FDA recommendations on clopidogrel (Plavix) because of decreased response and PPI interactions

Pharmamotion has now a new page containing updates on  clopidogrel PPI interactions.

The FDA issued today an early communication about an ongoing safety review of the antiplatelet agent clopidogrel bisulfate (Plavix). The backgroung to this is the recent evidence of:

Here are the recommendations from the FDA until there is further information:

  • Healthcare providers should continue to prescribe and patients should continue to take clopidogrel as directed, because clopidogrel has demonstrated benefits in preventing blood clots that could lead to a heart attack or stroke.
  • Healthcare providers should re-evaluate the need for starting or continuing treatment with a PPI, including Prilosec OTC, in patients taking clopidogrel.
  • Patients taking clopidogrel should consult with their healthcare provider if they are currently taking or considering taking a PPI, including Prilosec OTC.

Source: Center for Drug Evaluation and Research. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix)

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.

laptop2


 

 

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos